microRNA-214的下调表达对不同种类淋巴瘤细胞耐药性的影响  

Effect of knockdown microRNA-214 on drug resistance of different lymphoma cell types

作　　者：陈建忠[1] 贾秀芹[1] 

机构地区：[1]聊城市人民医院药学部,山东聊城252000

出　　处：《中国临床药理学杂志》2017年第10期905-908,共4页The Chinese Journal of Clinical Pharmacology

基　　金：山东省药学会临床药学奥赛康中青年科研基金资助项目(Sdpa-ask-2013-05)

摘　　要：目的研究microRNA-214对不同种类淋巴瘤细胞耐药性的影响。方法选择几种不同的淋巴瘤细胞,分别命名为Jurkat细胞实验组、OCI-Ly3细胞实验组及Raji细胞实验组,将健康人外周血淋巴细胞(Scr)作为对照组。细胞分别被敲除miR-214并给予不同的药物刺激。用荧光定量PCR法检测不同淋巴瘤细胞内miR-214的表达量;以CCK-8法检测敲除miR-214后的淋巴瘤细胞存活率;以MTT比色法检测敲除miR-214后不同淋巴瘤细胞对不同药物的敏感性;以蛋白质免疫印迹法检测BCL11B蛋白表达水平;用荧光素酶报告技术检测BCL11B是否为miR-214的靶基因。结果 Jurkat、OCI-Ly3及Raji细胞在实验组的miR-214的表达量分别为27.21±1.37,17.13±2.11,19.31±2.46,均明显高于对照组的1.17±0.28,差异有统计学意义(均P<0.05)。敲除miR-214后,与对照组的Scr细胞存活率(86±12)%相比,Jurkat、OCI-Ly3及Raji细胞在实验组的细胞存活率分别为(42±13)%,(65±11)%,(58±7)%,差异有统计学意义(均P<0.05)。抑制miR-214表达后,对照组Scr细胞对阿霉素、环磷酰胺、柔红霉素、丝裂霉素C和长春新碱的耐药敏感性分别为0.46±0.11,1.96±0.13,1.15±0.22,3.90±0.52,0.52±0.15,Jurkat细胞对5种药物的耐药敏感性分别为0.32±0.07,0.76±0.16,0.73±0.13,2.36±0.16,0.37±0.06,OCI-Ly3细胞对5种药物的耐药敏感性分别为0.28±0.06,0.91±0.12,0.55±0.09,2.01±0.36,0.23±0.07,Raji细胞对5种药物的耐药敏感性分别为0.36±0.04,0.82±0.08,0.64±0.07,3.31±0.21,0.35±0.05,与对照组比较,差异有统计学意义(P<0.05)。BCL11B是miR-214的靶基因。结论抑制miR-214表达能够降低不同种类淋巴瘤细胞的存活率,并降低白血病淋巴细胞的多药耐药性,这种作用可能与miR-214抑制其靶基因BCL11B的表达相关。Objective To explore the function of microRNA -214 on the drug resistance of different lymphoma cell types. Methods The Jur- kat cells, OCI - Ly3 cells and Raji ceils were selec-ted as the experimen- tal groups. The healthy peripheral blood lymphocytes （Scr） were selec- ted as the control group. The ceils were miR -214 knockdown and sti- mulated with different drugs. The expression of miR - 214 in different types of lymphoma cells was detected by real - time PCR. The cell via- bility of lymphoma cells after knockdown miR - 214 was detected by CCK- 8. The drug sensitivity was detected by methyl thiazolyl tetrazolium colorimetric method（MTT） assay. The BCL11B protein levels was detected by Western blot. The luciferase reporter assay was used to detect whether BCLIIB was the target gene of miR -214. Results The miR -214 expression in the experimental groups of Jurkat,Oci - ly3 and Raji cells were 27.21 ± 1.37,17.13 ± 2. 11,19.31±2. 46, which were significantly higher than those in control group of 1.17 ± 0. 28, the difference was statistical significance （P 〈 0. 05 ）. After knockout miR - 214, compared with the cell viability in control group （ 86 ±12 ） %, the cell viability of Jurkat, OCI- Ly3 and Raji were （42 ±13）%, （65 ± 11 ）%, （58 ± 7）%, the difference were significantly decreased （ P 〈 0. 05 ）. The drug sensitivity of Scr cells （ control group） to doxorubicin, cyclophosphamide, daunorubicin, mitomyein C and vincristine were 0.46 ± 0. 11,1.96± 0. 13,1.15± 0. 22,3.90 ± 0.52,0.52 ± 0. 15, respectively. The drug sensitivity of Jurkat cells to five drugs were 0. 32±0. 07,0. 76±0. 16,0. 73±0. 13,2. 36±0. 16,0. 37±0. 06. The drug sensitivity of OCI - Ly3 cells to the five drugs were 0.28 ±0. 06,0. 91 ±0. 12,0. 55±0. 09,2.01 ±0. 36, 0.23±0.07, respectively. The drug sensitivity of Raji cells to five drugs were 0. 36±0.04,0, 82±0. 08,0. 64±0. 07, 3.31±0. 21,0.35 ±0. 05, respectively. Which indicated that the drug sensitivity of lymphoma cells to variou

关 键 词：淋巴瘤 小分子核糖核酸-214 多药耐药性 

分 类 号：R97[医药卫生—药品]